Dexcom Stock Soars on Earnings. Ozempic Isn't the Threat It Was Supposed to Be
The maker of continuous glucose monitoring devices said there was no sign weight-loss drugs were hurting demand for its products.
Danielle Antalffy Jacob Sonenshine Courtesy Dexcom Article Normal Medical Equipment Supplies Healthcare Life Sciences
Source: marketwatch.com